Kindstar Globalgene finds bargain in solid tumor testing acquisition
The testing services provider’s proposed $31.3 million purchase price for AnchorDx represents a heavy discount to the company’s earlier valuations Key Takeaways: Kindstar Globalgene’s proposed acquisition of AnchorDx would allow…
Recent Articles
RELATED ARTICLES
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK -
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
- Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
-
Nissin warns of steep profit slide but sees solid core business
1475.HK
-
CARsgen seeks cell therapy breakthrough but stays in the red for now
2171.HK
